Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,890 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study.
Moore AM, Nooruddin Z, Reveles KR, Datta P, Whitehead JM, Franklin K, Alkadimi M, Williams MH, Williams RA, Smith S, Reichelderfer R, Cotarla I, Brannman L, Frankart A, Mulrooney T, Hsieh K, Simmons DJ, Jones X, Frei CR. Moore AM, et al. Curr Oncol. 2023 Sep 13;30(9):8411-8423. doi: 10.3390/curroncol30090611. Curr Oncol. 2023. PMID: 37754526 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38580274
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: simmons d. Pharmacoecon Open. 2022 Nov;6(6):811-822. doi: 10.1007/s41669-022-00338-2. Epub 2022 Aug 29. Pharmacoecon Open. 2022. PMID: 36036344 Free PMC article.
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: simmons d. Pharmacoecon Open. 2022 Nov;6(6):899. doi: 10.1007/s41669-022-00372-0. Pharmacoecon Open. 2022. PMID: 36107308 Free PMC article. No abstract available.
Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trial.
Haque MM, Tannous WK, Herman WH, Immanuel J, Hague WM, Teede H, Enticott J, Cheung NW, Hibbert E, Nolan CJ, Peek MJ, Wong VW, Flack JR, Mclean M, Sweeting A, Gianatti E, Kautzky-Willer A, Jürgen Harreiter, Mohan V, Backman H, Simmons D; TOBOGM Consortium. Haque MM, et al. Among authors: simmons d. EClinicalMedicine. 2024 Apr 24;71:102610. doi: 10.1016/j.eclinm.2024.102610. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38813447 Free PMC article.
A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity-dependent synaptic and microglial transcriptomic changes in a late-stage Alzheimer's mouse model.
Latif-Hernandez A, Yang T, Raymond-Butler R 3rd, Losada PM, Minhas PS, White H, Tran KC, Liu H, Simmons DA, Langness V, Andreasson KI, Wyss-Coray T, Longo FM. Latif-Hernandez A, et al. Among authors: simmons da. Alzheimers Dement. 2024 May 23. doi: 10.1002/alz.13857. Online ahead of print. Alzheimers Dement. 2024. PMID: 38779814
1,890 results